Clinical efficacy of treating pains suffered from metastatic bone cancer with composite kushen injection and pamidronate disodium injection / 中国综合临床

Objective To explore the clinical efficacy of treating pains suffered from metastatic bone cancer with composite kushen injection and pamidronate disodium injection.Methods The clinical information of 60 cases of metastatic bone cancer patients suffered with pains was collected retrospectively.Thirty patients were assigned to the treatment group and 30 to the control group according to the treatment they underwent.The control group were treated with pamidronate disodium injection for 3 cycle,the treatment group were additionaly treated with composite kushen injection.The differences of two groups cases were compared in respect of the relief of pains and the changes of performance status (PS) and the incidence of adverse effects after treatment for 3 cycles.Results The objective remission rate of bone pain was 60.0％ (18/30) in the treatment group,which was significantly higher than that of 30.0％ (9/30) in the control group was higher( x2 =5.455,P=0.020 ).The incidence of adverse effect was 40.0％ (12/30) in the treatment group and 46.6％ (14/30) in the control group,with no significant difference between the two groups( x2 =0.271,P =0.602).In the treatment group the performance status of patients was( 2.30 ± 0.70 ) after treatment,which was better than that of( 1.80 ± 0.80 )before treatment(t =15.000,P =0.042),wheras there was no significant difference on performance status in the control group.Conclusion Kushen injection has synergistic effect with pamidronate disodium injection in treating pains with matstatic bone cancer.It could improve the short term efficacy,and significantly relief the pain and improve the quality of life.

Impact of pamidronate disodium on the calcification of vascular smooth muscle cells induced by hyperphosphate / 中华肾脏病杂志

Objective To investigate the protective effect and mechanism of pamidronate disodium on calcification in rat vascular smooth muscle cells (RVSMCs) induced by hyperphosphate.Methods RVSMCs were placed in various culture mediam, including normal phosphate medium (Pi 1.4 mmol/L), high phosphate medium (Pi 4.5 mmol/L), different pamidronate disodium concentrations medium (Pi 4.5 mmol/L+pamidronate disodium 10-5, 10-6, 10-7 mmol/L). Calcium content and cell protein content were quantified by the O-cresolphthalein complexone method and BCA protein assay respectively. Calcification was visualized by yon Kossa staining, and cbfα-1,osteocalcin were quantified by Western blotting. Results After culture for 3 days, calcium content in high phosphate group were much higher than that in control group, and pamidronate disodium groups had a lower calcium content compared with high phosphate group (all P＜0.05).Calcium deposit in RVSMCs was greater in high phosphate group, while pamidronate disodium groups revealed obviously decreased deposit (all P＜0.05). Protein expression of cbfα-1 and osteocalcin in pamidronate disodium groups was much lower than that in high phosphate group.Conclusion Pamidronate disodium can protect RVSMCs from phosphate-induced calcification in vitro, which may be associated with the blockage of transformation of RVSMCs into osteoblast.

Clinical observation on zoledronic acid in treatment of the pain of metastatic bone cancer / 中国医师进修杂志

0.05 ) .In group A and group B ,the mean time to pain relief was (3.46?2.66) days and (4.35?1.83) days respectively , and the mean duration of the pain relief was (28.4?2.35) days and ( 15.6 ?3.85) days respectively , with no significant difference between the two groups (P0.05). Conclusions Zoledronic acid has a perfect therapeutic effect for the bone pain caused by metastatic bone cancer, with long duration of the pain relief and mild side effects. Zoledronic acid is an effcctive drug for metastatic bone cancer.

A clinical study of different administration of pamidronate in the patients with painful bone metastases due to lung cancer / 医学研究生学报

Objective: To compare the efficacy and safety of different administration of pamidronate for relieving bone pain and to improve the living quality in Chinese patients with painful bone metastases due to lung cancer. Methods:96 patients with painful bone metastases due to lung cancer were randomly enrolled to group A (150 mg) or group B (90 mg). There were 53 patients receiving 150 mg of pamidronate(34 pts for 2 days and 19 patients for 5 days administration). 43 (patients) receiving 90 mg of pamidronate. Results:There were 84.9% of patients relieving bone pain in group A and (67.4%) in group B (P=0.043). The score measuring bone pain decreased from 6.47?1.45 to (3.28?)1.71 in group A and from 6.21?1.49 to 3.49?2.88 in group B after injection of pamidronate , and the mean duration for pain relief were 28.00 days and 21.00 days respectively(P

In vivo Effect of Systemic pam-idronate Disodium on bo_ne Resorption in Experimental Cholesteatoma / 대한이비인후과학회지

BACKGROUND AND OBJECTIVES: Bone resorption of adjacent structures in aural cholesteatoma is mostly responsible for serious complication of the disease. Recent researches have been aimed at preventing bone resorption with tools of non-surgical therapy. The effect of pam-idronate disodium on systemic bone resorption is mainly attributed by its function against osteoclast recruitment and activation. In this study, we investigated the effect of systemic pam-idronate disodium on localized osteoclastic bone resorption in experimental cholesteatoma. MATERIAL AND METHODS: Experimental cholesteatomas were induced in 40 mongolian gerbils. pam-idronate disodium (Aredia(R), Ciba-Geigy Limited)were injected subcutaneously once a week in 20 gerbils (treated group)and none were injected in the other 20 gerbils (untreated group). pam-idronate disodium were injected with a dose of 2 mg/kg in 10 of the treated group (low dose group) and with a dose of 4 mg/kg in the remainder (high dose group). Gerbils were sacrificed at 12 weeks (3 month group) or 17 weeks (4 month group) after the injection. Harvested temporal bones were examined by light microscope and transmission electron microscope. RESULTS: The clinical stage of cholesteatoma tended to be more advanced in the untreated group than in the treated group although it was not statistically significant. Scores of osteoclast number per total bone length in millimeter were lower in the treated group than in the untreated, although the percentage of surface occupied by osteoclasts per total bone surface were not different between the groups. CONCLUSION: These results will provide fundamental data for further studies on the prevention and treatment of osteoclastic bone resorption in aural cholesteatoma.

Treatment of Postoperative Bone Metastasis of Non-small Cell Lung Cancer with Domestic Pamidronate Disodium / 中国药房

0.05).The effectual time for pain relief was2～17days(4.1days in av?erage).Serum calcium level declined after treatment and reduction of bone radioactive isotope collection was found in34pa?tients.The follow-up periods ranged from3months to30months.Fratures were found only in two patients.CONCLUSION:Domestic pamidronate disodium has satisfactory therapeutic effect on postoperative bone metastasis of non-small cell lung cancer.

Content Determination of Pamidronate Disodium by RP-HPLC / 中国药房

OBJECTIVE: To establish a RP-HPLC method for the determination of pamidronate disodium. METHODS: The determination was performed on C18 column with acetonitrile-0.4% sodium hydroxide solution of EDTA-Na2 (14∶86) as mobile phase at a flow rate of 0.6mL?min-1,the sample size was 10?L and the detection was performed by fluorescence detector with excitation wavelength at 395nm and emission wavelength at 480nm. RESULTS: The linear range of pamidronate disodium was 7.2～16.8?g?mL-1(r=0.999 8,n=9),the recovery rate was 100.11%(RSD=0.7%, n=9). CONCLUSIONS: The established method is simple and accurate.